Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative intramasseteric methylprednisolone for postoperative sequelae of lower third molar surgery
2024-520422-11-00Phase 4Authorised
- Sponsor
- Semmelweis University
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in postoperative pain, post-operative inflammation and edema comparing Preoperative intramasseteric Solu-Medrol with Preoperative intramasseteric placebo (2 arms). Primary endpoint: Postoperative sequelae after lower third molar surgery. Planned start Jan 2025; status: authorised.
02
Drugs
methylprednisolone sodium succinate
03
Conditions
postoperative painpost-operative inflammationedema
Beyond the preview
Go deeper on 2024-520422-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520422-11-00.